Canadian oncogenic human papillomavirus cervical infection prevalence: Systematic review and meta-analysis

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Tricco, Andrea C ^a   Ng, Carmen H ^b   Gilca, Vladimir ^c   Anonychuk, Andrea ^d   Pham, Ba' ^e,f   Berliner, Shirra ^g  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Bethesda system; Cervical cancer; Human papillomavirus; Meta analysis; Systematic review

Indexed keywords

AGE DISTRIBUTION; AGING; ARTICLE; CANADA; CANCER SCREENING; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; NONHUMAN; ONCOGENIC CERVICAL HUMAN PAPILLOMAVIRUS INFECTION; PAPILLOMAVIRUS INFECTION; PREVALENCE; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; UTERINE CERVICITIS; UTERINE CERVIX CANCER; ADOLESCENT; ADULT; AGED; CLASSIFICATION; FEMALE; GENETICS; GENOTYPE; IMMUNOLOGY; ISOLATION AND PURIFICATION; META ANALYSIS; MIDDLE AGED; PAPILLOMA VIRUS; PATHOGENICITY; REVIEW; UTERINE CERVIX TUMOR; UTILIZATION REVIEW; VACCINATION; VIROLOGY;

VIRUS DNA; WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CANADA; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 80052588999     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-235     Document Type: Article

References (89)

1. Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003, 14-19.
2. Munoz N, Bosch FX, de SS, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527. 10.1056/NEJMoa021641, 12571259.
3. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El GF, brahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V. A review of human carcinogens--Part B: biological agents. Lancet Oncol 2009, 10:321-322. 10.1016/S1470-2045(09)70096-8, 19350698.
4. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F, 10451482.
5. Bernard HU, Calleja-Macias IE, Dunn ST. Genome variation of human papillomavirus types: phylogenetic and medical implications. Int J Cancer 2006, 118:1071-1076. 10.1002/ijc.21655, 16331617.
6. Aubin F, Pretet JL, Jacquard AC, Saunier M, Carcopino X, Jaroud F, Pradat P, Soubeyrand B, Leocmach Y, Mougin C, Riethmuller D. Human papillomavirus genotype distribution in external acuminata condylomata: a Large French National Study (EDiTH IV). Clin Infect Dis 2008, 47:610-615. 10.1086/590560, 18637758.
7. Shepherd LJ, Bryson SC. Human papillomavirus--lessons from history and challenges for the future. J Obstet Gynaecol Can 2008, 30:1025-1033.
8. Canadian Cancer Society's Steering Committee Canadian cancer statistics 2009. Toronto 2009, Canadian Cancer Society's Steering Committee.
9. Health Canada Cervical cancer screening in Canada: 1998 Surveillance report. Ottawa 2002, Health Canada.
10. Gupta S, Roos LL, Walld R, Traverse D, Dahl M. Delivering equitable care: comparing preventive services in Manitoba. Am J Public Health 2003, 93:2086-2092. 10.2105/AJPH.93.12.2086, 1448157, 14652339.
11. Johnston GM, Boyd CJ, MacIsaac MA. Community-based cultural predictors of Pap smear screening in Nova Scotia. Can J Public Health 2004, 95:95-98.
12. Katz SJ, Hofer TP. Socioeconomic disparities in preventive care persist despite universal coverage. Breast and cervical cancer screening in Ontario and the United States. JAMA 1994, 272:530-534. 10.1001/jama.272.7.530, 8046807.
13. Lofters A, Glazier RH, Agha MM, Creatore MI, Moineddin R. Inadequacy of cervical cancer screening among urban recent immigrants: a population-based study of physician and laboratory claims in Toronto, Canada. Prev Med 2007, 44:536-542. 10.1016/j.ypmed.2007.02.019, 17467782.
14. McDonald JT, Kennedy S. Cervical cancer screening by immigrant and minority women in Canada. J Immigr Minor Health 2007, 9:323-334. 10.1007/s10903-007-9046-x, 17345152.
15. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006, 119:1095-1101. 10.1002/ijc.21955, 16586444.
16. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, Matchar DB. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000, 132:810-819.
17. Cervarix™ Product Monograph, August 2010.
18. Gardasil™ Product Monograph, May 2011.
19. Franco EL, Ferenczy A. Cervical cancer screening following the implementation of prophylactic human papillomavirus vaccination. Future Oncol 2007, 3:319-327. 10.2217/14796694.3.3.319, 17547527.
20. Franco EL, Cuzick J, Hildesheim A, de SS. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 2006, 24(Suppl 3):S3171-S3/177.
21. Erickson LJ, De WP, Farand L. An analytical framework for immunization programs in Canada. Vaccine 2005, 23:2470-2476. 10.1016/j.vaccine.2004.10.029, 15752833.
22. Howlett RI, Miller AB, Pasut G, Mai V. Defining a strategy to evaluate cervical cancer prevention and early detection in the era of HPV vaccination. Prev Med 2009, 48:432-437. 10.1016/j.ypmed.2008.12.022, 19167422.
23. Higgins JPT, Green S, . editors Cochrane Handbook for Systematic Reviews of Interventions 2009, The Cochrane Collaboration, Version 5.0.2 [updated September 2009]., editors., http://www.cochrane-handbook.org
24. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339:b2535. 10.1136/bmj.b2535, 2714657, 19622551.
25. Sampson M, McGowan J, Lefebvre C, Moher D, Grimshaw J. PRESS: Peer Review of Electronic Search Strategies. Ottawa 2008,
26. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2010,
27. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003, 88:63-73. 10.1038/sj.bjc.6600688, 2376782, 12556961.
28. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121:621-632. 10.1002/ijc.22527, 17405118.
29. Duggan MA, Inoue M, McGregor SE, Nation JG. A comparison of cervical scrapes for HPV typing by dot-blot hybridization obtained by wood and plastic spatulas. Journal of Virological Methods 1990, 29:267-277. 10.1016/0166-0934(90)90054-J, 2176222.
30. Peng HQ, Roth P, Caussy D, Rawls W. Comparison of the Cytobrush and cotton swabs in sampling cervical cells for filter in situ hybridization detection of human papillomavirus types 16 and 18 DNA. Acta cytologica 1988, 32:311-313.
31. Sellors JW, Mahony JB, Kaczorowski J, Lytwyn A, Bangura H, Chong S, Lorincz A, Dalby DM, Janjusevic V, Keller JL. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group.[see comment]. CMAJ Canadian Medical Association Journal 2000, 163:503-508.
32. Sellors JW, Karwalajtys TL, Kaczorowski JA, Mahony JB, Lytwyn A, Chong S, Sparrow J, Lorincz A, . Survey of HPV in Older Ontario Women (SHOOW) Group Prevalence of infection with carcinogenic human papillomavirus among older women. CMAJ Canadian Medical Association Journal 2002, 167:871-873. Survey of HPV in Older Ontario Women (SHOOW) Group.
33. Sanderson S, Tatt ID, Higgins JP. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol 2007, 36:666-676. 10.1093/ije/dym018, 17470488.
34. Bishop FL, Prescott P, Chan YK, Saville J, von EE, Lewith GT. Prevalence of complementary medicine use in pediatric cancer: a systematic review. Pediatrics 2010, 125:768-776. 10.1542/peds.2009-1775, 20308209.
35. Sellors JW, Lorincz AT, Mahony JB, Mielzynska I, Lytwyn A, Roth P, Howard M, Chong S, Daya D, Chapman W, Chernesky M. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions. CMAJ Canadian Medical Association Journal 2000, 163:513-518.
36. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T, Young N. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002, 287:2114-2119. 10.1001/jama.287.16.2114, 11966386.
37. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188. 10.1016/0197-2456(86)90046-2, 3802833.
38. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995, 87:796-802. 10.1093/jnci/87.11.796, 7791229.
39. Moore RA, Ogilvie G, Fornika D, Moravan V, Brisson M, mirabbasi-Beik M, Kollar A, Burgess T, Hsu R, Towers L, Lo J, Matisic J, Brooks-Wilson A. Prevalence and type distribution of human papillomavirus in 5,000 British Columbia women--implications for vaccination. Cancer Causes Control 2009, 20:1387-1396. 10.1007/s10552-009-9365-4, 2746887, 19475481.
40. Antonishyn NA, Horsman GB, Kelln RA, Saggar J, Severini A. The impact of the distribution of human papillomavirus types and associated high-risk lesions in a colposcopy population for monitoring vaccine efficacy. Arch Pathol Lab Med 2008, 132:54-60.
41. Brisson J, Morin C, Fortier M, Roy M, Bouchard C, Leclerc J, Christen A, Guimont C, Penault F, Meisels A. Risk factors for cervical intraepithelial neoplasia: differences between low- and high-grade lesions. American Journal of Epidemiology 1994, 140:700-710.
42. Caussy D, Marrett LD, Worth AJ, McBride M, Rawls WE. Human papillomavirus and cervical intraepithelial neoplasia in women who subsequently had invasive cancer. CMAJ Canadian Medical Association Journal 1990, 142:311-317.
43. Duggan MA, McGregor SE, Benoit JL, Inoue M, Nation JG, Stuart GC. The human papillomavirus status of invasive cervical adenocarcinoma: a clinicopathological and outcome analysis. Hum Pathol 1995, 26:319-325. 10.1016/0046-8177(95)90065-9, 7890285.
44. Duggan MA, McGregor SE, Stuart GC, Morris S, Chang-Poon V, Schepansky A, Honore L. The HPV determinants of CIN I. European Journal of Gynaecological Oncology 1997, 18:117-123.
45. Feoli-Fonseca JC, Oligny LL, Brochu P, Simard P, Falconi S, Yotov WV. Human papillomavirus (HPV) study of 691 pathological specimens from Quebec by PCR-direct sequencing approach. Journal of Medical Virology 2001, 63:284-292. 10.1002/1096-9071(200104)63:4<284::AID-JMV1003>3.0.CO;2-H, 11241459.
46. Franco E, Bergeron J, Villa L, Arella M, Richardson L, Arseneau J, Stanimir G. Human papillomavirus DNA in invasive cervical carcinomas and its association with patient survival: a nested case-control study. Cancer Epidemiology, Biomarkers & Prevention 1996, 5:271-275.
47. Guijon F, Paraskevas M, McNicol P. Human papillomavirus infection and the size and grade of cervical intraepithelial neoplastic lesions associated with failure of therapy. International Journal of Gynaecology & Obstetrics 1993, 42:137-142. 10.1016/0020-7292(93)90627-9, 21926912.
48. Hamlin-Douglas L. Prevalence and determinants of human papillomavirus (HPV) infection in Inuit women of Nunavik, Quebec. PhD Thesis 2008, McGill University.
49. Hankins C, Coutlee F, Lapointe N, Simard P, Tran T, Samson J, Hum L. Prevalence of risk factors associated with human papillomavirus infection in women living with HIV. Canadian Women's HIV Study Group. CMAJ Canadian Medical Association Journal 1999, 160:185-191.
50. Healey SM, Aronson KJ, Mao Y, Schlecht NF, Mery LS, Ferenczy A, Franco EL. Oncogenic human papillomavirus infection and cervical lesions in aboriginal women of Nunavut, Canada. Sexually Transmitted Diseases 2001, 28:694-700. 10.1097/00007435-200112000-00006, 11725224.
51. Kapala J, Jang D, Patel J, Biers K, Smieja M, Chernesky M. Pap cytopathology and the presence of high-risk human papillomavirus in SurePath liquid preservative and Digene cervical sampler specimens. Journal of Virological Methods 2007, 142:223-225. 10.1016/j.jviromet.2007.01.028, 17320978.
52. Koushik A, Ghosh A, Duarte-Franco E, Forest P, Voyer H, Matlashewski G, Coutlee F, Franco EL, . Biomarkers of Cervical Cancer Risk (BCCR) Study Team The p53 codon 72 polymorphism and risk of high-grade cervical intraepithelial neoplasia. Cancer Detection & Prevention 2005, 29:307-316. 10.1016/j.cdp.2005.06.007, 21928360, Biomarkers of Cervical Cancer Risk (BCCR) Study Team.
53. Lytwyn A, Sellors JW, Mahony JB, Daya D, Chapman W, Ellis N, Roth P, Lorincz AT, Gafni A. Comparison of human papillomavirus DNA testing and repeat Papanicolaou test in women with low-grade cervical cytologic abnormalities: a randomized trial. HPV Effectiveness in Lowgrade Paps (HELP) Study No. 1 Group. CMAJ Canadian Medical Association Journal 2000, 163:701-707.
54. Mayrand MH, Duarte FE, Coutlée F, Rodrigues I, Walter SD, Ratnam S, Franco EL, . CCCaST-Study-Group Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). International journal of cancer Journal international du cancer 2006, 119:615-623. CCCaST-Study-Group.
55. Michael P. PCR screening for human papillomavirus infections, and evaluation of the estimated infection prevalence for a population of females. PhD Thesis 1999, Laurentian University.
56. Ogilvie G, Krajden M, Maginley J, Isaac-Renton J, Hislop G, Elwood-Martin R, Sherlock C, Taylor D, Rekart M. Feasibility of self-collection of specimens for human papillomavirus testing in hard-to-reach women. CMAJ Canadian Medical Association Journal 2007, 177:480-483.
57. Ratnam S, Hogan K, Hankins C. Prevalence of HIV infection among pregnant women in Newfoundland. CMAJ: Canadian Medical Association Journal 1996, 154:1027-1032. 1487592, 8625023.
58. Richardson H, Franco E, Pintos J, Bergeron J, Arella M, Tellier P. Determinants of low-risk and high-risk cervical human papillomavirus infections in Montreal University students. Sexually Transmitted Diseases 2000, 27:79-86. 10.1097/00007435-200002000-00005, 10676974.
59. Richardson H, Kelsall G, Tellier P, Voyer H, Abrahamowicz M, Ferenczy A, Coutlee F, Franco EL. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiology, Biomarkers & Prevention 2003, 12:485-490.
60. Rohan T, Mann V, McLaughlin J, Harnish DG, Yu H, Smith D, Davis R, Shier RM, Rawls W. PCR-detected genital papillomavirus infection: prevalence and association with risk factors for cervical cancer. Int J Cancer 1991, 49:856-860. 10.1002/ijc.2910490609, 1660038.
61. Tran-Thanh D, Koushik A, Provencher D, Drouin P, Dubuc-Lissoir J, Gauthier P, Allaire G, Kornegay J, Franco E, Coutlee F. Detection of human herpes virus type 6 DNA in precancerous lesions of the uterine cervix. J Med Virol 2002, 68:606-610. 10.1002/jmv.10229, 12376970.
62. Young TK, McNicol P, Beauvais J. Factors associated with human papillomavirus infection detected by polymerase chain reaction among urban Canadian aboriginal and non-aboriginal women.[see comment]. Sexually Transmitted Diseases 1997, 24:293-298. 10.1097/00007435-199705000-00011, 9153740.
63. Aho J, Hankins C, Tremblay C, Lang F, Forest P, Pourreaux K, Rouah F, Coutlee F. Molecular analysis of human papillomavirus type 52 isolates detected in the genital tract of human immunodeficiency virus-seropositive and -seronegative women. J Infect Dis 2003, 188:1517-1527. 10.1086/379198, 14624377.
64. Aho J, Hankins C, Tremblay C, Forest P, Pourreaux K, Rouah F, Coutlee F. Genomic polymorphism of human papillomavirus type 52 predisposes toward persistent infection in sexually active women. J Infect Dis 2004, 190:46-52. 10.1086/420787, 15195242.
65. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003, 89:101-105. 10.1038/sj.bjc.6601024, 2394204, 12838308.
66. Coutlee F, Hankins C, Lapointe N. Comparison between vaginal tampon and cervicovaginal lavage specimen collection for detection of human papillomavirus DNA by the polymerase chain reaction. The Canadian Women's HIV Study Group. Journal of Medical Virology 1997, 51:42-47. 10.1002/(SICI)1096-9071(199701)51:1<42::AID-JMV7>3.0.CO;2-S, 8986948.
67. Duggan MA, Inoue M, McGregor SE, Stuart GC, Morris S, Chang-Poon V, Schepansky A, Honore L. A paired comparison of dot blot hybridization and PCR amplification for HPV testing of cervical scrapes interpreted as CIN 1. European Journal of Gynaecological Oncology 1994, 15:178-187.
68. Duggan MA, Benoit JL, McGregor SE, Nation JG, Inoue M, Stuart GC. The human papillomavirus status of 114 endocervical adenocarcinoma cases by dot blot hybridization. Hum Pathol 1993, 24:121-125. 10.1016/0046-8177(93)90289-S, 8381762.
69. Duggan MA, McGregor SE, Stuart GC, Morris S, Chang-Poon V, Schepansky A, Honore L. The natural history of CIN I lesions. European Journal of Gynaecological Oncology 1998, 19:338-344.
70. Duggan MA, McGregor SE, Stuart GC, Morris S, Chang-Poon V, Schepansky A, Honore L. Predictors of co-incidental CIN II/III amongst a cohort of women with CIN I detected by a screening Pap test. European Journal of Gynaecological Oncology 1998, 19:209-214.
71. Gagnon S, Hankins C, Tremblay C, Pourreaux K, Forest P, Rouah F, Coutlee F, . The Canadian Women's HIV Study Group Polymorphism of human papillomavirus type 31 isolates infecting the genital tract of HIV-seropositive and HIV-seronegative women at risk for HIV infection. Journal of Medical Virology 2005, 75:213-221. 10.1002/jmv.20259, 15602735, The Canadian Women's HIV Study Group.
72. Healey SM. Human papillomavirus infection and cervical dysplasia in Nunavut. PhD Thesis 2000, Queen's University.
73. Healey SM, Aronson K, Mao Y, Franco EL. Human papillomavirus and cervical dysplasia in Nunavut: prelude to a screening strategy. International Journal of Circumpolar Health 2004, 63(Suppl):201.
74. Karwalajtys T, Howard M, Sellors JW, Kaczorowski J. Vaginal self sampling versus physician cervical sampling for HPV among younger and older women. Sexually Transmitted Infections 2006, 82:337-339. 10.1136/sti.2005.019430, 2564727, 16877589.
75. Lytwyn A, Sellors JW, Mahony JB, Daya D, Chapman W, Howard M, Roth P, Lorincz AT, Gafni A, Walter SD. Adjunctive human papillomavirus testing in the 2-year follow-up of women with low-grade cervical cytologic abnormalities: a randomized trial and economic evaluation. Archives of pathology & laboratory medicine 2003, 127:1169-1175.
76. Mahmud SM, Koushik A, Duarte-Franco E, Costa J, Fontes G, Bicho M, Coutlee F, Franco EL, . Biomarkers of Cervical Cancer Risk Study Team Haptoglobin phenotype and risk of cervical neoplasia: a case-control study. Clinica Chimica Acta 2007, 385:67-72. Biomarkers of Cervical Cancer Risk Study Team.
77. Oligny LL, Feoli-Fonseca JC, Brochu P, Simard P, Falconi S, Yotov WV. Human papillomavirus PCR direct sequencing study of cervical precancerous lesions in Quebec children. Sexually Transmitted Infections 2001, 77:391. 10.1136/sti.77.5.391, 1744372, 11588297.
78. Schaffer A, Koushik A, Trottier H, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L, Gotlieb W, Ferenczy A, Coutlee F, Pollak MN, Franco EL. Insulin-like growth factor-I and risk of high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 2007, 16:716-722. 10.1158/1055-9965.EPI-06-0924, 17416762.
79. Sellors JW, Karwalajtys TL, Kaczorowski J, Mahony JB, Lytwyn A, Chong S, Sparrow J, Lorincz A, . Survey of HPV in Ontario Women Group Incidence, clearance and predictors of human papillomavirus infection in women.[see comment][comment]. CMAJ Canadian Medical Association Journal 2003, 168:421-425. Survey of HPV in Ontario Women Group.
80. Tran-Thanh D, Provencher D, Koushik A, Duarte-Franco E, Kessous A, Drouin P, Wheeler CM, Dubuc-Lissoir J, Gauthier P, Allaire G, Vauclair R, Dipaolo JA, Gravitt P, Franco E, Coutlee F. Herpes simplex virus type II is not a cofactor to human papillomavirus in cancer of the uterine cervix. Am J Obstet Gynecol 2003, 188:129-134. 10.1067/mob.2003.66, 12548206.
81. Richardson H, Abrahamowicz M, Tellier PP, Kelsall G, du BR, Ferenczy A, Coutlee F, Franco EL. Modifiable risk factors associated with clearance of type-specific cervical human papillomavirus infections in a cohort of university students. Cancer Epidemiology, Biomarkers & Prevention 2005, 14:1149-1156. 10.1158/1055-9965.EPI-04-0230, 21890444.
82. Clifford GM, Goncalves MA, Franceschi S. Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS 2006, 20:2337-2344. 10.1097/01.aids.0000253361.63578.14, 17117020.
83. Smith JS, Melendy A, Rana RK, Pimenta JM. Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health 2008, 43:S5-25, S25.
84. Marrett LD, Innes M, Howlett R, Cotterchio M. Insight on Cancer: News and information on cervical cancer. Toronto 2005,
85. National Advisory Committee on Immunization (NACI) National Advisory Committee on Immunization (NACI) statement on human papillomavirus vaccine 2007, National Advisory Committee on Immunization (NACI).
86. Woltman KJ, Newbold KB. Immigrant women and cervical cancer screening uptake: a multilevel analysis. Can J Public Health 2007, 98:470-475.
87. Maruthur NM, Bolen SD, Brancati FL, Clark JM. The association of obesity and cervical cancer screening: a systematic review and meta-analysis. Obesity (Silver Spring) 2009, 17:375-381.
88. Kuhn L, Denny L, Pollack A, Lorincz A, Richart RM, Wright TC. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst 2000, 92:818-825. 10.1093/jnci/92.10.818, 10814677.
89. Howell-Jones R, Bailey A, Beddows S, Sargent A, de SN, Wilson G, Anton J, Nichols T, Soldan K, Kitchener H. Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England. Br J Cancer 2010, 103:209-216. 10.1038/sj.bjc.6605747, 2906740, 20628396.